HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imahori, Y. Articles by Ido, T. Search for Related Content PubMed PubMed Citation Articles by Imahori, Y. Articles by Ido, T.

Fluorine-18-Labeled Fluoroboronophenylalanine PET in Patients with Glioma

Department of Neurosurgery, Kyoto Prefectural University of Medicine, Kyoto; Kyoto University Research Reactor Institute, Osaka; Cyclotron Unit, Nishijin Hospital, Kyoto; Cyclotron and RI Center, Tohoku University, Sendai, Japan

Correspondence: For correspondence or reprints contact: Yoshio Imahori, MD, PhD, Department of Neurosurgery, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku 602, Kyoto, Japan.

ABSTRACT

We synthesized fluorine-18-labeled fluoroboronophenylalanine (¹⁸F-¹⁰B-FBPA), an analog of boronophenylalanine (¹⁰B-BPA), and characterized its pharmacokinetics in patients with glioma. We conducted PET studies on three types of gliomas to clarify the relationship between tumor grade and each rate constant [K1 (ml/g/min), k2 (min^–1) and k3 (min^–1)], and here, we discuss the metabolism of the ¹⁰B-BPA analog (¹⁸F-¹⁰B-FBPA). Methods: Thirty-three cases of primary gliomas were studied by dynamic PET using DL-¹⁸F-¹⁰B-FBPA or L-¹⁸F-¹⁰B-FBPA. Dynamic PET images of ¹⁸F-¹⁰B-FBPA incorporation into tumors were obtained, and the arterial blood samplings were performed in all cases. Results: When the dynamic PET data were represented as Gjedde-Patlak plots, there was a positive slope, suggesting the involvement of the putative metabolic pool of this tracer. A three-compartment model using rate constants (K1, k2 and k3) was used for the kinetic analysis. The accumulation of ¹⁸F-¹⁰B-FBPA was found to correlate with the degree of malignancy, and the L form of ¹⁸F-¹⁰B-FBPA was taken up better than was the DL form. The results of dynamic PET analysis suggested that K1 (measuring amino acid transport process) is a major factor determining the accumulation of ¹⁸F-¹⁰B-FBPA. A comparison of the rate constants revealed that k3 (metabolic process)did not correlate with the degree of malignancy. The absence of evident differences in k3 between DL and L forms suggests that k3 represents phenomena that are not dependent on the native form of L. Conclusion: These PET data will be of practical use for diagnosis of malignancy and direct prediction of the effectiveness of boron neutron capture therapy using ¹⁰B-BPA.

Key Words: fluoroboronophenylalanine • PET • boron neutron capture therapy

This article has been cited by other articles:

				N FUWA, M SUZUKI, Y SAKURAI, K NAGATA, Y KINASHI, S MASUNAGA, A MARUHASHI, Y IMAHORI, T KODAIRA, H TACHIBANA, et al. Treatment results of boron neutron capture therapy using intra-arterial administration of boron compounds for recurrent head and neck cancer Br. J. Radiol., September 1, 2008; 81(969): 749 - 752. [Abstract] [Full Text] [PDF]

				C.-H. Hsieh, Y.-F. Chen, F.-D. Chen, J.-J. Hwang, J.-C. Chen, R.-S. Liu, J.-J. Kai, C.-W. Chang, and H.-E. Wang Evaluation of Pharmacokinetics of 4-Borono-2-18F-Fluoro-L-Phenylalanine for Boron Neutron Capture Therapy in a Glioma-Bearing Rat Model with Hyperosmolar Blood-Brain Barrier Disruption J. Nucl. Med., November 1, 2005; 46(11): 1858 - 1865. [Abstract] [Full Text] [PDF]

				R. F. Barth, J. A. Coderre, M. G. H. Vicente, and T. E. Blue Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects Clin. Cancer Res., June 1, 2005; 11(11): 3987 - 4002. [Abstract] [Full Text] [PDF]

				H.-E. Wang, A.-H. Liao, W.-P. Deng, P.-F. Chang, J.-C. Chen, F.-D. Chen, R.-S. Liu, J.-S. Lee, and J.-J. Hwang Evaluation of 4-Borono-2-18F-Fluoro-L-Phenylalanine-Fructose as a Probe for Boron Neutron Capture Therapy in a Glioma-Bearing Rat Model J. Nucl. Med., February 1, 2004; 45(2): 302 - 308. [Abstract] [Full Text] [PDF]

				Y. Takahashi, Y. Imahori, and K. Mineura Prognostic and Therapeutic Indicator of Fluoroboronophenylalanine Positron Emission Tomography in Patients with Gliomas Clin. Cancer Res., December 1, 2003; 9(16): 5888 - 5895. [Abstract] [Full Text] [PDF]

				S. Chandra, G. W. Kabalka, D. R. Lorey II, D. R. Smith, and J. A. Coderre Imaging of Fluorine and Boron from Fluorinated Boronophenylalanine in the Same Cell at Organelle Resolution by Correlative Ion Microscopy and Confocal Laser Scanning Microscopy Clin. Cancer Res., August 1, 2002; 8(8): 2675 - 2683. [Abstract] [Full Text] [PDF]